Compared to normal tissue, GLO-1 was significantly upregulated in 28 tumors, including GBM (Tumor: 6.73 0.48, Normal: 5.37 1.31, p = 6.7e75), GBMLGG (Tumor: 6.58 0.41, Normal: 5.37 1.31, p = 8.5e216), LGG (Tumor: 6.53 0.37, Normal: 5.37 1.31, p = 3.7e178), BRCA (Tumor: 6.83 0.68, Normal: 5.37 1.31, p = 3.7e179), EGFR (Tumor: 6.83 0.68, Normal: 5.37 1.31, p = 3.7e179), CESC (Tumor: 6.44 0.63, Normal: 5.91 0.21, p = 1.2e4), LUAD (Tumor: 6.49 0.68, Normal: 5.87 0.93, p = 3.5e42), ESCA (Tumor: 6.78 0.62, Normal: 5.25 1.26, p = 6.3e84), STES (Tumor: 6.44 0.68, Normal: 5.13 1.38, p = 3.6e165), COAD (Tumor: 6.40 0.52, Normal: 4.99 1.67, p = 2.6e90), COADREAD (Tumor: 6.43 0.55, Normal: 5.01 1.66, p = 1.9e102), PRAD (Tumor: 7.81 0.90, Normal: 6.52 1.03, p = 4.7e34), STAD (Tumor: 6.29 0.65, Normal: 4.75 1.64, p = 6.8e64), HNSC (Tumor: 6.49 0.60, Normal: 5.72 0.54, p = 9.7e15), LUSC (Tumor: 6.52 0.66, Normal: 5.87 0.93, p = 9.2e48), LIHC (Tumor: 5.86 0.76, Normal: 4.87 0.60, p = 9.8e38), WT (Tumor: 7.21 0.38, Normal: 6.07 1.49, p = 3.5e35), SKCM (Tumor: 6.14 0.83, Normal: 5.78 0.39, p = 4.1e11), BLCA (Tumor: 6.13 0.74, Normal: 5.78 0.33, p = 1.3e3), THCA (Tumor: 5.64 0.43, Normal: 5.29 0.92, p = 7.8e28), READ (Tumor: 6.50 0.62, Normal: 6.02 0.34, p = 4.8e3), OV (Tumor: 6.59 1.08, Normal: 6.11 0.26, p = 5.6e14), PAAD (Tumor: 5.58 0.46, Normal: 3.62 1.58, p = 1.0e53), TGCT (Tumor: 6.01 0.89, Normal: 4.47 0.63, p = 1.3e37), and UCS (Tumor: 6.72 0.60, Normal: 5.74 0.29, p = 5.2e-18)
People in Spring, TX, trust Z Med Clinic for IV Glutathione therapy
GSH may also hold benefit for the treatment of parotitis, cervical dysplasia, Alzheimer's disease, Parkinson's disease, aminoquinoline toxicity, gentamycin toxicity, puromycin toxicity, aminoglycoside nephrotoxicity, paracetamol, acetaminophen and phenacetin toxicity
This phenomenon is called the "bloodbraintumor barrier," and it can block chemotherapy agents from reaching tumor lesions and offer a barrier to the treatment of CNS tumors ( Fig
